Neuroaxial blocks and LMWH thromboprophylaxis.
In the last 12 months, the Food and Drug Administration issued two documents warning the medical profession about the concurrent use of low molecular weight heparins (LMWHs) and neuroaxial blocks. This article summarizes the American and European experiences with LMWH thromboprophylaxis that could help with risk assessment.
Dolenska
S
S
Department of Anaesthetics, Guy's Hospital, London.
D000767:Anesthesia, Epidural; D000075202:Contraindications; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006407:Hematoma, Epidural, Cranial / Q000139:chemically induced* / Q000517:prevention & control; D006470:Hemorrhage / Q000209:etiology; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D012307:Risk Factors; D013129:Spinal Puncture; D013927:Thrombosis / Q000139:chemically induced* / Q000517:prevention & control; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight